8 months ago
3
Glenmark Pharmaceuticals, done a subsidiary, has entered into an exclusive licence and collaboration statement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody cause conjugate (ADC).
Under the agreement, Glenmark volition get exclusive rights to make and commercialise Trastuzumab Rezetecan successful respective countries, excluding Mainland China, USA, Europe, Japan and Russia among others. Glenmark volition wage an upfront outgo of $18 million.
Hengrui is eligible to person regulatory and commercialized milestone payments of up to $1.093 billion. Based connected the nett income of Trastuzumab Rezetecan wrong the licensed territory, Glenmark volition wage corresponding royalties to Hengrui.
Trastuzumab Rezetecan is Hengrui’s HER2-targeted ADC. In May 2025, it was approved successful China for the attraction of big patients with HER2 (ERBB2) activating mutations successful unresectable locally precocious oregon metastatic non-small compartment lung crab (NSCLC) who person received astatine slightest 1 anterior systemic therapy.
In September, the caller denotation for Trastuzumab Rezetecan successful bosom crab was accepted by China’s NMPA for review. Trastuzumab Rezetecan has been included successful the NMPA’s Breakthrough Therapy Designation database for 9 indications, covering NSCLC, bosom cancer, gastric oregon gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies, Glenmark said successful a merchandise connected Wednesday.
